propidium iodide has been researched along with myricetin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Andrisano, V; Arce, EM; Barenys, M; Bartolini, M; Bolognesi, ML; Brea, J; De Simone, A; Decker, M; Ginex, T; Gómez-Catalán, J; Griñán-Ferré, C; Loza, MI; Luque, FJ; Martínez, N; Mattellone, A; Muñoz-Torrero, D; Naldi, M; Pallàs, M; Pérez, B; Pont, C; Sabate, R; Scheiner, M; Soriano-Fernández, Y | 1 |
2 other study(ies) available for propidium iodide and myricetin
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
Topics: Alzheimer Disease; Aminoquinolines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Brain; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Dynamics Simulation; Molecular Structure; Neuroprotective Agents; Recombinant Proteins; Structure-Activity Relationship; tau Proteins | 2021 |